title: New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
abstract: OBJECTIVE
  Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines.
  
  
  METHODS
  Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines.
  
  
  RESULTS
  29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = -0.564, p ≤ 0.01).
  
  
  CONCLUSIONS
  The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
authors.affiliation: Department of Medical Oncology and.
authors.forename: W
authors.initials: W
authors.lastname: van Boxtel
authors.forename: B F
authors.initials: BF
authors.lastname: Bulten
authors.forename: A M C
authors.initials: AM
authors.lastname: Mavinkurve-Groothuis
authors.forename: L
authors.initials: L
authors.lastname: Bellersen
authors.forename: C M P W
authors.initials: CM
authors.lastname: Mandigers
authors.forename: L A B
authors.initials: LA
authors.lastname: Joosten
authors.forename: L
authors.initials: L
authors.lastname: Kapusta
authors.forename: L F
authors.initials: LF
authors.lastname: de Geus-Oei
authors.forename: H W M
authors.initials: HW
authors.lastname: van Laarhoven
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood*; D001943:Breast Neoplasms / Q000188:drug therapy; D066126:Cardiotoxicity / Q000097:blood* / Q000175:diagnosis / Q000209:etiology; D002318:Cardiovascular Diseases / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis; D003520:Cyclophosphamide / Q000009:adverse effects; D000077143:Docetaxel; D004317:Doxorubicin / Q000009:adverse effects; D004452:Echocardiography; D004569:Electroencephalography; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D037502:Galectin 3 / Q000097:blood*; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D012680:Sensitivity and Specificity; D043823:Taxoids / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D037502:Galectin 3; D010446:Peptide Fragments; D043823:Taxoids; D014409:Tumor Necrosis Factor-alpha; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide
keywords: Anthracyclines; biological markers; breast neoplasms; echocardiography; heart failure; pro-brain natriuretic peptide